Xtant Medical Holdings, Inc.
No SEC Form 4 filings for $XTNT in the last 30 days.
See all $XTNT insider activity →Xtant Medical's stock rose 16.36% to $0.384 after BioHorizons agreed to distribute its Prolifica dental product. The deal grants BioHorizons exclusive rights in the U.S. and Canada. Xtant's market value increased by $7.6 million, but revenue impact remains unspecified. Xtant reported a 35% revenue drop in Q2, with a net loss of $9.4 million.
Xtant Medical Holdings reported Q2 2026 revenue headwinds tied to divestitures to Companion Spine and the end of certain license revenue. Biologics softness and amniotic membrane weakness persisted, while 17 new Dilon reps weighed on sales. Full-year 2026 guidance was cut to $99M-$103M; cash fell to $9.9M. Gross margin was 57.9%.
Xtant Medical Holdings, Inc. (XTNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xtant Medical Reports Second Quarter 2026 Financial Results Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast to
Over the past 7 days, alphai's AI scored 1 news story mentioning XTNT (Xtant Medical Holdings, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent XTNT coverage spans financial news, earnings and market movers.
Deal expands Xtant's market reach into dental, potentially boosting revenue and margins.
Guidance reduction and gross margin pressure raise near-term downside risk, while HEMOBLAST gross recognition transition and Trivium early momentum are potential offsets.
The 8-K discloses a guidance reset tied to weaker biologics revenue and amnio headwinds, plus a new Dilon distribution deal and Trivium Shaped launch.
Routine shareholder-meeting outcomes with no new operating or financial guidance; likely limited incremental impact on near-term trading.
New product launch may broaden Xtant’s spine graft offering and support procedure adoption.
alphai scores every news story that mentions XTNT with an AI model for sentiment and relevance, and aggregates insider trades from Xtant Medical Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Xtant Medical's stock rose 16.36% to $0.384 after BioHorizons agreed to distribute its Prolifica dental product. The deal grants BioHorizons exclusive rights in the U.S. and Canada. Xtant's market value increased by $7.6 million, but revenue impact remains unspecified. Xtant reported a 35% revenue drop in Q2, with a net loss of $9.4 million.
2 min readXtant Medical Holdings reported Q2 2026 revenue headwinds tied to divestitures to Companion Spine and the end of certain license revenue. Biologics softness and amniotic membrane weakness persisted, while 17 new Dilon reps weighed on sales. Full-year 2026 guidance was cut to $99M-$103M; cash fell to $9.9M. Gross margin was 57.9%.
7 min readXtant Medical Holdings, Inc. (XTNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xtant Medical Reports Second Quarter 2026 Financial Results Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast to
6 min readXtant Medical Holdings, Inc. (XTNT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. Xtant Medical Holdings, Inc. (the “Company”) held an Annual Meeting of Stockholders (the “Annual Meeting”) on August 7, 2026. As of the close of business on June 9, 2026, the record date for the Annual Meeting, there
2 min readBecker’s reports six spine and orthopedic biologics developments in the first half of 2026. Ventris Medical received added patent coverage for its Backpack system. Xtant Medical launched the Trivium shaped bone graft. MTF Biologics and Kolosis BIO launched DBX Fiber. Medtronic’s Infuse bone graft received FDA premarket approval for one- and two-level transforaminal lumbar interbody spinal fusions. Kolosis Bio and MTF Biologics launched Summit Matrix. Tetrous received a U.S. patent for EnFix impl
2 min readXtant Medical Holdings reported a Q1 2026 revenue of $20.9 million, a significant drop from $32.9 million in Q1 2025, primarily due to the sale of assets and non-recurring license revenue. Despite the decline, the company announced strategic moves like strengthening its balance sheet through asset sales, expanding into the hemostatics market, and integrating Dilon’s sales force, leading to an increased full-year 2026 revenue guidance of $101 million to $105 million.
2 min readXtant Medical Holdings received an additional $10.7 million from Companion Spine, finalizing the total aggregate purchase price of $21.4 million for the sale of Coflex® assets and Paradigm OUS businesses. This payment includes $8.2 million for an unsecured promissory note and $2.2 million from working capital and other adjustments. Xtant Medical plans to use these funds to reduce long-term debt and increase cash liquidity, allowing them to focus on their higher-margin biologics business.
2 min read
